Labeling Monoclonal Antibody with α-emitting 211At at High Activity Levels via a Tin Precursor-Reference-Cited by-同舟云学术

Labeling Monoclonal Antibody with α-emitting 211At at High Activity Levels via a Tin Precursor

Published:2020-09-01 Issue:7 Volume:35 Page:511-519
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Vaidyanathan Ganesan¹,Pozzi Oscar R.¹,Choi Jaeyeon¹,Zhao Xiao-Guang¹,Murphy Shawn¹,Zalutsky Michael R.¹

Affiliation:

1. Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/cbr.2019.3204

Reference29 articles.

1. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α-particles or Auger electrons

2. Applications of 211At and 223Ra in Targeted Alpha-Particle Radiotherapy

3. Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2—A Phase I Study

4. Absorbed Doses and Risk Estimates of 211At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients

5. Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics;Nuclear Medicine and Biology;2024-07

2. Copper-mediated astatination of 211At-labelled prostate-specific membrane antigen probes in the presence of basic salts;Tetrahedron;2024-04

3. Status of α-emitter Radioimmunoconjugates for Targeted Therapy;Current Radiopharmaceuticals;2023-06

4. Tumor Targeting of ²¹¹At-Labeled Antibody under Sodium Ascorbate Protection against Radiolysis;Molecular Pharmaceutics;2022-12-27

5. Recent progress of astatine-211 in endoradiotherapy: Great advances from fundamental properties to targeted radiopharmaceuticals;Chinese Chemical Letters;2022-07